Bayer Oncology Dubs American Society of Clinical Oncology "Turning Point" for Cancer Efforts

If one were to list the top cancer drugmakers of all time, it’s fair to say Bayer wouldn’t make the top 10. Despite the German drug giant’s leadership position across the healthcare spectrum—from over-the-counter aspirin to diabetes glucose-testing meters—it has never made much of a splash in cancer. In 2000, Bayer’s (OTCBB: BAYRY) top executives decided to change that by making a major commitment to oncology and boosting its cancer development efforts in a few key sites, including its R&D facility in Montville, NJ.